Metropolis 医疗保健获得246.83Crore的核心诊断,以扩大印度的癌症测试范围。 Metropolis Healthcare acquires Core Diagnostics for ₹246.83 crore to expand cancer testing in India.

印度第二大诊断公司大都会医疗公司已同意以246.83亿卢比收购核心诊断公司, 以提高其先进的癌症检测能力, 并扩大其在印度北部和东部的业务. Metropolis Healthcare, India's second-largest diagnostics firm, has agreed to acquire Core Diagnostics for ₹246.83 crore to enhance its advanced cancer testing capabilities and expand its presence in Northern and Eastern India. 这笔交易将由55%的现金和45%的股票供资,预计将在60天之内完成,但须经股东批准。 The deal, to be financed with 55% cash and 45% stock, is expected to complete within 60 days, subject to shareholder approval. 核心诊断于2012年建立,在200个城市运作,提供1 300多项高端检测,主要是癌症检测。 Core Diagnostics, founded in 2012, operates in 200 cities and offers over 1,300 high-end tests, mainly for cancer.